



Alpine Immune Sciences Announces Poster Presentation at the 2018 AACR Annual Meeting

March 14, 2018

SEATTLE--(BUSINESS WIRE)--Mar. 14, 2018-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing treatments for cancer and autoimmune/inflammatory diseases, today announced the company will present a poster at the 2018 American Association for Cancer Research ("AACR") Annual Meeting taking place April 14 - 18, 2018 in Chicago, Illinois.

The poster, entitled "CD80 vlgD-Fc proteins combine checkpoint antagonism and costimulatory signaling for potent antitumor immunity," will highlight preclinical data evaluating a novel immuno-oncology molecule derived from the company's vlgD™ platform. An abstract of the presentation will be available on AACR website after March 14, 2018.

Presentation details are as follows:

Session Category: Clinical Research

Session Title: Immune Checkpoints 4

Session Date and Time: Tuesday, April 17, 2018 – 1:00 PM - 5:00 PM

Location: McCormick Place South, Exhibit Hall A, Poster Section 25

Poster Board Number: 5

A copy of the poster will be made available on the Company's website after it is presented.

About Alpine Immune Sciences, Inc.

Alpine Immune Sciences, Inc. is focused on developing novel protein-based immunotherapies using its proprietary variant Ig Domain (vlgD) platform technology. The vlgD platform is designed to interact with multiple targets including many present in the immune synapse. Alpine's vlgDs are developed using a process known as directed evolution, which produces proteins capable of either enhancing or diminishing an immune response and thereby may potentially apply therapeutically to cancer, autoimmune, and inflammatory diseases. Alpine has also developed Transmembrane Immunomodulatory Protein (TIP) technology, based on the vlgD platform, to potentially enhance engineered cellular therapies. For more information, visit www.alpineimmunesciences.com.

View source version on businesswire.com: <http://www.businesswire.com/news/home/20180314005269/en/>

Source: Alpine Immune Sciences, Inc.

For Alpine Immune Sciences, Inc.

Investors:

W2O pure

Courtney Dugan, 212-257-6723

cdugan@w2ogroup.com

or

Media:

W2O

Jennifer Paganelli, 347-658-8290

jpaganelli@w2ogroup.com